A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY‑318).

Authors

J. Randolph Hecht

David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

J. Randolph Hecht , Aleix Prat , Miklos Pless , Antonio Cubillo , Aitana Calvo , Steven Raman , Jason Alan Chesney , Chunxu Liu , Emily Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.

First Author: Brian Gastman

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).

First Author: J. Randolph Hecht

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

First Author: Daniel Olson

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

First Author: Martin Reck